Key result
A positive family history of primary movement disorders was a significant predictor for the lifetime prevalence of neuroleptic-induced extrapyramidal symptoms (p=0.03).
Why the study?
Does a family history of primary movement disorders predict neuroleptic-induced extrapyramidal symptoms in psychiatric in-patients?
Observational (n=100)
No
Does a family history of primary movement disorders predict neuroleptic-induced extrapyramidal symptoms in psychiatric in-patients?
Answers are grounded in this paper and cite their sources.
A positive family history of primary movement disorders, along with age and duration of neuroleptic exposure, significantly predicts the occurrence of neuroleptic-induced extrapyramidal symptoms.
BACKGROUND: A genetic susceptibility to extrapyramidal symptoms caused by treatment with neuroleptic medication has been suggested. AIMS: To identify predictor variables for neuroleptic-induced extrapyramidal symptoms, particularly considering family history of primary movement disorders. METHOD: We investigated 100 in-patients receiving a stable neuroleptic medication with regard to occurrence of extrapyramidal symptoms, drug history and detailed family history of primary movement disorders. RESULTS: Step-wise logistic regression analysis revealed that a positive family history was a significant predictor for lifetime prevalence of extrapyramidal symptoms, including reported and currently observed symptoms. The duration of exposure to neuroleptic medication and age were further predictors. CONCLUSIONS: Our findings underline the notion of genetic susceptibility for secondary extrapyramidal symptoms and suggest possible shared genetic factors in primary and secondary movement disorders as well as psychotic disorders.
No takes yet. Share an insight, caveat, or question.
Lencer et al. (2004) conducted an observational in Psychiatric disorders requiring neuroleptic medication (n=100). Positive family history of primary movement disorders vs. Negative family history of primary movement disorders was evaluated on Lifetime prevalence of extrapyramidal symptoms (p=0.03). A positive family history of primary movement disorders was a significant predictor for the lifetime prevalence of neuroleptic-induced extrapyramidal symptoms (p=0.03).
Synapse has enriched 10 related papers. Consider them for comparative context: